Zogenix expects little fall-out from end of Astellas tie-up for Sumavel
This article was originally published in Scrip
Executive Summary
Zogenix and Astellas Pharma US have agreed to the early termination of their US co-promotion agreement for the migraine drug Sumavel DosePro (sumatriptan injection), but Zogenix expects the move to have only a minimal impact on the brand's cash flow in 2012.